Michael J. Fox Foundation

The assay could allow clinicians to diagnose synucleinopathies like Parkinson's disease without requiring a lumbar puncture to collect cerebrospinal fluid.

The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.